Skip to main content
Erschienen in: BMC Pediatrics 1/2024

Open Access 01.12.2024 | Research

Aberrant SOX10 and RET expressions in patients with Hirschsprung disease

verfasst von: Gunadi, Verrell Christopher Amadeus, Fadila Dyah Trie Utami, Fiqih Vidiantoro Halim, Nabilah Anisa Novebri, Rahaditya Alrasyidi Hanggoro, Avinindita Nura Lestari, Kristy Iskandar, Andi Dwihantoro, Eko Purnomo

Erschienen in: BMC Pediatrics | Ausgabe 1/2024

Abstract

Background

HSCR is a complex genetic disorder characterized by the absence of ganglion cells in the intestine, leading to a functional obstruction. It is due to a disruption of complex signaling pathways within the gene regulatory network (GRN) during the development of the enteric nervous system (ENS), including SRY-Box Transcription Factor 10 (SOX10) and REarranged during Transfection (RET). This study evaluated the expressions of SOX10 and RET in HSCR patients in Indonesia.

Methods

Total RNA of 19 HSCR ganglionic and aganglionic colons and 16 control colons were analyzed using quantitative real-time polymerase chain reaction for SOX10 and RET with GAPDH as the reference gene. Livak’s method (2−ΔΔCT) was used to determine the expression levels of SOX10 and RET.

Results

Most patients were males (68.4%), in the short aganglionosis segment (78.9%), and had undergone transanal endorectal pull-through (36.6%). There were significant upregulated SOX10 expressions in both ganglionic (2.84-fold) and aganglionic (3.72-fold) colon of HSCR patients compared to controls’ colon (ΔCT 5.21 ± 2.04 vs. 6.71 ± 1.90; p = 0.032; and ΔCT 4.82 ± 1.59 vs. 6.71 ± 1.90; p = 0.003; respectively). Interestingly, the RET expressions were significantly downregulated in both ganglionic (11.71-fold) and aganglionic (29.96-fold) colon of HSCR patients compared to controls’ colon (ΔCT 12.54 ± 2.21 vs. 8.99 ± 3.13; p = 0.0004; and ΔCT 13.90 ± 2.64 vs. 8.99 ± 3.13; p = 0.0001; respectively).

Conclusions

Our study shows aberrant SOX10 and RET expressions in HSCR patients, implying the critical role of SOX10 and RET in the pathogenesis of HSCR, particularly in the Indonesian population. Our study further confirms the involvement of SOX10-RET within the GNR during the ENS development.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
SOX10
SRY-Box Transcription Factor 10
RET
REarranged during Transfection
GAPDH
glyceraldehyde-3-phosphate dehydrogenase
WS4
Waardenburg syndrome type 4, HSCR:Hirschsprung disease
qPCR
quantitative real-time polymerase chain reaction

Background

Hirschsprung disease (HSCR) is a complex congenital disorder characterized by the absence of intrinsic ganglion cells in the intestinal tract, starting distally and extending proximally to variable lengths [14]. Its incidence is higher in Indonesia (3.1:10,000) than in other populations, including Asians (2.8:10,000) and Caucasians (1.5:10,000) [1, 5]. These facts might be due to the greater risk allele frequency of REarranged during Transfection (RET) rs2506030 in Indonesia compared to other populations [6].
HSCR has been associated with more than 35 genes, including SRY-box transcription factor 10 (SOX10) and RET [15]. However, the thirty-five genes only provide 62% of the frequency of HSCR. Therefore, the pathogenesis of HSCR in the remaining patients remains unclear [2, 5]. HSCR can be associated with the alteration of gene expressions [7, 8].
SOX10 is a transcription factor that affects RET expression by binding to one of its cis-regulatory elements (CREs) located in intron 1 of RET: RET-7, RET-5.5, and RET + 3. Therefore, in the presence of variants affecting CREs, SOX10 is not able to bind anymore, leading to decreased RET expression [7]. Here, we aimed to evaluate the expressions of SOX10 and RET in HSCR patients and compare them with the controls.

Materials and methods

Patients

Twenty patients under 18 years old presenting with non-syndromic HSCR whose ganglionic and aganglionic colons were collected during pull-through surgery are included in this study. We did not have any genetic data for those 20 HSCR patients. Sixteen control colon samples were collected during stoma closure for anorectal malformation patients. One HSCR patient was excluded due to low-quality RNA; thus, 19 of the total RNA of HSCR patients were further analyzed.
Each patient’s parents completed a written informed consent form before participating in this study. This study was approved by the Institutional Review Board of the Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital (KE/FK/0442/EC/2022 and KE/FK/0758/EC/2022). All experiments were conducted in conformity with the necessary legislation and guidelines.

Total RNA isolation and quantitative real-time polymerase chain reaction

Total RNA extraction of the HSCR patient’s colon (aganglionic and ganglionic) and the control colon was done by using a total RNA Mini Kit (Tissue) (Geneaid Biotech Ltd., New Taipei City, Taiwan). The samples were stored at − 80 °C for future use.
One-step quantitative real-time polymerase chain reaction (qPCR) was performed using Kapa SBYR Fast qRT-PCR One Step Kit Universal (Kapa Biosystems, Massachusetts, USA) and BioRad CFX Real-Time PCR System (California, USA). The primers used for qPCR were as follows: SOX10 5’-ATGAACGCCTTCATGGTGTGGG-3’ (forward) and 5’-CGCTTGTCACTTTCGTTCAGCAG-3’ (reverse) [9], and RET 5′-CTGCCAAGTCCCGATG-3′ (forward) and 5′-TGGAGTACGCCAAATACG-3′ (reverse) [10]. The GAPDH gene was used as an internal control with the following primers: 5′-GCACCGTCAAGGCTGAGAAC-3′ (forward) and 5′-TGGTGAAGACGCCAGTGGA-3′ (reverse). As a reference gene, GAPDH has been validated in a diverse set of several tissues representing different organs, including the liver of biliary atresia and other diseases (gallbladder hydrops, omphalocele, internal bleeding, liver abscess, and choledochal cyst) and ganglionic and aganglionic colon of HSCR and anorectal malformation colon patients in our previous studies [11, 12]. The GAPDH showed a constant expression in a significant variation of human tissue samples [11, 12].

Statistical analysis

The expression level of SOX10 and RET was measured using the Livak method (2− ΔΔCT). The data is presented as mean ± SD and analyzed using an independent t-test; p < 0.05 was considered significant. All statistical analyses were performed using the IBM SPSS version 23 (Chicago, USA).

Results

Patient characteristics

Nineteen subjects were involved in this study. Most patients were males (68.4%) and short aganglionosis segment (78.9%) (Table 1).
Table 1
Characteristics of HSCR patients in this study
Characteristics
N (%), median (IQR)
Gender
 Male
13 (68.4)
 Female
6 (31.6)
Age at pull-through (months)
18 (2.25–75)
Aganglionosis degree
  Short
15 (78.9)
 Long
3 (15.8)
  Total colon
1 (5.3)
Pull-through approach
  Transanal endorectal
7 (36.8)
  Duhamel
6 (31.6)
  Transanal Swenson-like
5 (26.3)
  Transabdominal Soave
1 (5.3)

SOX10 expressions in HSCR patients

There were significant upregulated SOX10 expressions in both ganglionic (2.84-fold) and aganglionic (3.72-fold) colon of HSCR patients compared to controls’ colon (p = 0.032 and 0.003, respectively) (Table 2; Fig. 1).
Table 2
SOX10 expressions in HSCR patients and controls
SOX10
ΔCT ± SD
ΔΔCT (95% CI)
Fold change
p-value
Ganglionic colon
5.21 ± 2.04
-1.50 (-2.87 – (-0.14))
2.84
0.032*
Aganglionic colon
4.82 ± 1.59
− 1.90 (-3.10 – (-0.69))
3.72
0.003*
Control colon
6.71 ± 1.90
   
*p < 0.05 is considered statistically significant; CI, confidence interval; CT, cycle threshold; SD, standard deviation

RET expressions in HSCR patients

Subsequently, we determined the RET expressions in HSCR patients and controls. Interestingly, significant downregulated RET expressions were noted in both ganglionic (11.71-fold) and aganglionic (29.96-fold) colon of HSCR patients compared to controls’ colon (p = 0.0004 and 0.0001, respectively) (Table 3; Fig. 2).
Table 3
RET expressions in HSCR patients and controls
RET
ΔCT ± SD
ΔΔCT (95% CI)
Fold change
p-value
Ganglionic colon
12.54 ± 2.21
3.55 (1.71–5.39)
11.71
0.0004*
Aganglionic colon
13.90 ± 2.64
4.91 (3.01–6.80)
29.96
0.0001*
Control colon
8.99 ± 3.13
   
*p < 0.05 is considered statistically significant; CI, confidence interval; CT, cycle threshold; SD, standard deviation

Discussion

Our study is able to show the aberrant SOX10 and RET expressions in HSCR patients. A previous study showed lower SOX10 expressions were associated with hypertrophic nerve trunks in HSCR patients [8]. They suggested that the aberrant SOX10 expressions might involve HSCR pathogenesis via interaction with other neurotrophic factors in non-syndromic patients without any pathogenic variants in the SOX10 gene. Our study provides new evidence of the aberrant SOX10 expressions in HSCR patients from a different population from a previous study [9]. In addition, most SOX10 pathogenic variants were found in syndromic HSCR patients [13]. Interestingly, a recent study revealed that three common variants within CREs of RET decreased the binding of transcription factors, including SOX10, to those three CREs. These interactions caused the decrease of RET expressions and disruption of other HSCR and enteric nervous system (ENS) genes within the RET–EDNRB GRN [7].
SOX10 is a gene encoding a member of the SRY-related HMG-box (SOX) family of transcription factors that regulate embryonic development and determine cell fate. The SOX10 protein acts as a nucleocytoplasmic shuttle protein, essential for neurogenesis and neural crest cells (NCCs) development [13]. SOX10 has significant roles in the development of NCCs, one of which is regulating the migration of NCCs, which form the ganglionic plexus of the ENS [14]. SOX10 helps ensure the survival and pluripotency of NCCs during and after migration and contributes to determining their fates and differentiation [1416]. It is also known that direct SOX10 interaction with Cadherin-19 (Cdh19) mediates early sacral NCCs migration by forming cadherin-catenin complexes. These complexes interact with the cytoskeleton filamentous actin in the migration of NCCs [17].
SOX10 expression is regulated by several transcription factors, such as SOX9, Olig2, WNT, FoxD3, and Snail [16, 18]. Overexpression of SOX10 has been shown to inhibit the differentiation of NCCs [14, 18]. After the differentiation of the NCCs, SOX10 expression is maintained in enteric glial cells while downregulated in neurons and smooth muscle cells [14, 16].
Several weaknesses of our study were noted, including a small sample size, and our findings did not consider other ENS and HSCR gene expressions involved within the RET–EDNRB gene regulatory network (GRN). Two housekeeping genes should always be included to account for technical variations during qPCR. Our study only used GAPDH as an internal control. It is essential to conduct a further study to determine whether the increased SOX10 expressions are due to the increased glial cells or enhancement of SOX10 expressions in ENS cells. Moreover, it is also interesting to determine whether the increased SOX10 expressions due to the cell numbers of SOX10-expressing cells are changed or the SOX10 promoter activity is enhanced. In the postnatal period, SOX10 is mainly expressed in glial cells. The quantification of the glial cell population in the colon from patients and control is crucial. Checking aberrant expression of SOX10 in other cell types is also needed. Alternatively, an isolated explant or cell culture experiment is required. Using this system, it is possible to estimate promoter or enhancer activities of SOX10 and high levels of SOX10 in ENS cells. In addition, we do not validate the protein levels of SOX10, including immunohistochemistry, in HSCR patients due to limited resources. Pathogenic variants in GLI, resulting in upregulated Sox10 expression in vitro, have been detected in patients with non-syndromic HSCR [19]. Therefore, screening pathogenic variants in transcription factors regulating SOX10 in patients or estimating promoter or enhancer activities of SOX10 in isolated human ENS cells is essential.
SOX10 is required for RET expression, and decreased RET expression causes HSCR [7, 14, 20]. During the development of ENS, SOX10 controls specific genes, including RET, EDNRB, and SOX10 itself [14]. The decrease of RET expressions disrupts the other HSCR and enteric nervous system (ENS) genes within the RET–EDNRB GRN, including GATA2, SOX10, RARB, and NKX2.5 [21]. However, no direct evidence indicates that increased SOX10 leads to aganglionosis, i.e., HSCR. Interestingly, upregulated SOX10 expression promotes the migration of neural crest-like cells of the neural tube; however, it hampers their differentiation [22]. We further determined the RET expressions in our HSCR patients. Intriguingly, the expressions of RET were significantly downregulated in patients compared to controls. These decreased RET expressions might lead to HSCR. It is important and interesting to conduct a further study on how upregulated SOX10 causes decreased RET expression, resulting in HSCR.
Moreover, our findings might be beneficial during the surgical counseling to the parents that in a polygenic disorder, such as HSCR, a complex interaction between genes might result in different disease phenotypes. This evidence further confirms the complexity of the pathogenesis of HSCR, including the disruption of the GNR during the ENS development.

Conclusions

Our study shows aberrant SOX10 and RET expressions in HSCR patients, implying the critical role of SOX10 and RET in the pathogenesis of HSCR, particularly in the Indonesian population. Our study further confirms the involvement of SOX10-RET within the GNR during the ENS development.

Acknowledgements

We want to thank the patients, parents, and everyone who participated in the study and offered excellent technical support and help.

Declarations

This study was approved by the Institutional Review Board of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia (KE/FK/0442/EC/2022 and KE/FK/0758/EC/2022). The research has been performed following the Declaration of Helsinki. All parents or guardians signed written informed consent to participate in this study.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Tang CS, Karim A, Zhong Y, Chung PH, Tam PK. Genetics of Hirschsprung’s disease. Pediatr Surg Int. 2023;39(1):104.CrossRefPubMed Tang CS, Karim A, Zhong Y, Chung PH, Tam PK. Genetics of Hirschsprung’s disease. Pediatr Surg Int. 2023;39(1):104.CrossRefPubMed
2.
Zurück zum Zitat Tilghman JM, Ling AY, Turner TN, Sosa MX, Krumm N, Chatterjee S, et al. Molecular genetic anatomy and risk profile of Hirschsprung’s disease. N Engl J Med. 2019;380:1421–32.CrossRefPubMedPubMedCentral Tilghman JM, Ling AY, Turner TN, Sosa MX, Krumm N, Chatterjee S, et al. Molecular genetic anatomy and risk profile of Hirschsprung’s disease. N Engl J Med. 2019;380:1421–32.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Karim A, Tang CS, Tam P. The emerging genetic landscape of Hirschsprung disease and its potential clinical applications. Front Pediatr. 2021;9:638093.CrossRefPubMedPubMedCentral Karim A, Tang CS, Tam P. The emerging genetic landscape of Hirschsprung disease and its potential clinical applications. Front Pediatr. 2021;9:638093.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tam PK. Hirschsprung’s disease: a bridge for science and surgery. J Pediatr Surg. 2016;51:18–22.CrossRefPubMed Tam PK. Hirschsprung’s disease: a bridge for science and surgery. J Pediatr Surg. 2016;51:18–22.CrossRefPubMed
5.
Zurück zum Zitat Gunadi, Kalim AS, Iskandar K, Marcellus, Puspitarani DA, Diposarosa R, et al. Exome sequencing identifies novel genes and variants in patients with Hirschsprung disease. J Pediatr Surg. 2023;58(4):723–8.CrossRefPubMed Gunadi, Kalim AS, Iskandar K, Marcellus, Puspitarani DA, Diposarosa R, et al. Exome sequencing identifies novel genes and variants in patients with Hirschsprung disease. J Pediatr Surg. 2023;58(4):723–8.CrossRefPubMed
6.
Zurück zum Zitat Gunadi, Iskandar K, Makhmudi A, Kapoor A. Combined genetic effects of RET and NRG1 susceptibility variants on multifactorial Hirschsprung disease in Indonesia. J Surg Res. 2019;255:96–9.CrossRef Gunadi, Iskandar K, Makhmudi A, Kapoor A. Combined genetic effects of RET and NRG1 susceptibility variants on multifactorial Hirschsprung disease in Indonesia. J Surg Res. 2019;255:96–9.CrossRef
7.
Zurück zum Zitat Chatterjee S, Karasaki KM, Fries LE, Kapoor A, Chakravarti A. A multi-enhancer RET regulatory code is disrupted in Hirschsprung disease. Genome Res. 2021;31(12):2199–208.CrossRefPubMedPubMedCentral Chatterjee S, Karasaki KM, Fries LE, Kapoor A, Chakravarti A. A multi-enhancer RET regulatory code is disrupted in Hirschsprung disease. Genome Res. 2021;31(12):2199–208.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Sham MH, Lui VC, Fu M, Chen B, Tam PK. SOX10 is abnormally expressed in aganglionic bowel of Hirschsprung’s disease infants. Gut. 2001;49(2):220–6.CrossRefPubMedPubMedCentral Sham MH, Lui VC, Fu M, Chen B, Tam PK. SOX10 is abnormally expressed in aganglionic bowel of Hirschsprung’s disease infants. Gut. 2001;49(2):220–6.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Meganathan K, Jagtap S, Srinivasan SP, Wagh V, Hescheler J, Hengstler J, et al. Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells. Cell Death Dis. 2015;6:e1756.CrossRefPubMedPubMedCentral Meganathan K, Jagtap S, Srinivasan SP, Wagh V, Hescheler J, Hengstler J, et al. Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells. Cell Death Dis. 2015;6:e1756.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Yang D, Yang J, Li S, Jiang M, Cao G, Yang L, Zhang X, Zhou Y, Li K, Tang ST. Effects of RET, NRG1 and NRG3 polymorphisms in a Chinese Population with Hirschsprung Disease. Sci Rep. 2017;7:43222.ADSCrossRefPubMedPubMedCentral Yang D, Yang J, Li S, Jiang M, Cao G, Yang L, Zhang X, Zhou Y, Li K, Tang ST. Effects of RET, NRG1 and NRG3 polymorphisms in a Chinese Population with Hirschsprung Disease. Sci Rep. 2017;7:43222.ADSCrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Makhmudi A, Supanji R, Putra BP, Gunadi. The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients. Pediatr Surg Int. 2020;36(1):75–9.CrossRefPubMed Makhmudi A, Supanji R, Putra BP, Gunadi. The effect of APTR, Fn14 and CD133 expressions on liver fibrosis in biliary atresia patients. Pediatr Surg Int. 2020;36(1):75–9.CrossRefPubMed
12.
Zurück zum Zitat Gunadi KAS, Marcellus, Budi NYP, Iskandar K. The impact of NRG1 expressions and methylation on multifactorial Hirschsprung disease. BMC Pediatr. 2022;22(1):216.CrossRefPubMedPubMedCentral Gunadi KAS, Marcellus, Budi NYP, Iskandar K. The impact of NRG1 expressions and methylation on multifactorial Hirschsprung disease. BMC Pediatr. 2022;22(1):216.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Sánchez-Mejías A, Watanabe Y, M Fernández R, López-Alonso M, Antiñolo G, Bondurand N, et al. Involvement of SOX10 in the pathogenesis of Hirschsprung disease: report of a truncating mutation in an isolated patient. J Mol Med. 2010;8(5):507–14.CrossRef Sánchez-Mejías A, Watanabe Y, M Fernández R, López-Alonso M, Antiñolo G, Bondurand N, et al. Involvement of SOX10 in the pathogenesis of Hirschsprung disease: report of a truncating mutation in an isolated patient. J Mol Med. 2010;8(5):507–14.CrossRef
14.
Zurück zum Zitat Pingault V, Zerad L, Bertani-Torres W, Bondurand N. SOX10: 20 years of phenotypic plurality and current understanding of its developmental function. J Med Genet. 2022;59(2):105–14.CrossRefPubMed Pingault V, Zerad L, Bertani-Torres W, Bondurand N. SOX10: 20 years of phenotypic plurality and current understanding of its developmental function. J Med Genet. 2022;59(2):105–14.CrossRefPubMed
15.
Zurück zum Zitat Bhattarai C, Poudel PP, Ghosh A, Kalthur SG. Comparative role of SOX10 gene in the gliogenesis of central, peripheral, and enteric nervous systems. Differentiation. 2022;128:13–25.CrossRefPubMed Bhattarai C, Poudel PP, Ghosh A, Kalthur SG. Comparative role of SOX10 gene in the gliogenesis of central, peripheral, and enteric nervous systems. Differentiation. 2022;128:13–25.CrossRefPubMed
16.
Zurück zum Zitat Kim J, Lo L, Dormand E, Anderson DJ. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron. 2003;38(1):17–31.CrossRefPubMed Kim J, Lo L, Dormand E, Anderson DJ. SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuron. 2003;38(1):17–31.CrossRefPubMed
17.
Zurück zum Zitat Huang T, Hou Y, Wang X, Wang L, Yi C, Wang C, et al. Direct interaction of Sox10 with Cadherin-19 mediates early sacral neural crest cell migration: implications for enteric nervous system development defects. Gastroenterology. 2022;162(1):179–e19211.CrossRefPubMed Huang T, Hou Y, Wang X, Wang L, Yi C, Wang C, et al. Direct interaction of Sox10 with Cadherin-19 mediates early sacral neural crest cell migration: implications for enteric nervous system development defects. Gastroenterology. 2022;162(1):179–e19211.CrossRefPubMed
18.
Zurück zum Zitat Bondurand N, Sham MH. The role of SOX10 during enteric nervous system development. Dev Biol. 2013;382(1):330–43.CrossRefPubMed Bondurand N, Sham MH. The role of SOX10 during enteric nervous system development. Dev Biol. 2013;382(1):330–43.CrossRefPubMed
19.
Zurück zum Zitat Liu JA, Lai FP, Gui HS, Sham MH, Tam PK, Garcia-Barcelo MM, Hui CC, Ngan ES. Identification of GLI mutations in patients with Hirschsprung Disease that disrupt enteric nervous System Development in mice. Gastroenterology. 2015;149(7):1837–e18485.CrossRefPubMed Liu JA, Lai FP, Gui HS, Sham MH, Tam PK, Garcia-Barcelo MM, Hui CC, Ngan ES. Identification of GLI mutations in patients with Hirschsprung Disease that disrupt enteric nervous System Development in mice. Gastroenterology. 2015;149(7):1837–e18485.CrossRefPubMed
20.
Zurück zum Zitat Chatterjee S, Kapoor A, Akiyama JA, Auer DR, Lee D, Gabriel S, Berrios C, Pennacchio LA, Chakravarti A. Enhancer variants synergistically drive dysfunction of a Gene Regulatory Network in Hirschsprung Disease. Cell. 2016;167(2):355–e36810.CrossRefPubMedPubMedCentral Chatterjee S, Kapoor A, Akiyama JA, Auer DR, Lee D, Gabriel S, Berrios C, Pennacchio LA, Chakravarti A. Enhancer variants synergistically drive dysfunction of a Gene Regulatory Network in Hirschsprung Disease. Cell. 2016;167(2):355–e36810.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chatterjee S, Chakravarti A. A gene regulatory network explains RET-EDNRB epistasis in Hirschsprung disease. Hum Mol Genet. 2019;28(18):3137–47.CrossRefPubMedPubMedCentral Chatterjee S, Chakravarti A. A gene regulatory network explains RET-EDNRB epistasis in Hirschsprung disease. Hum Mol Genet. 2019;28(18):3137–47.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat McKeown SJ, Lee VM, Bronner-Fraser M, Newgreen DF, Farlie PG. Sox10 overexpression induces neural crest-like cells from all dorsoventral levels of the neural tube but inhibits differentiation. Dev Dyn. 2005;233(2):430–44.CrossRefPubMed McKeown SJ, Lee VM, Bronner-Fraser M, Newgreen DF, Farlie PG. Sox10 overexpression induces neural crest-like cells from all dorsoventral levels of the neural tube but inhibits differentiation. Dev Dyn. 2005;233(2):430–44.CrossRefPubMed
Metadaten
Titel
Aberrant SOX10 and RET expressions in patients with Hirschsprung disease
verfasst von
Gunadi
Verrell Christopher Amadeus
Fadila Dyah Trie Utami
Fiqih Vidiantoro Halim
Nabilah Anisa Novebri
Rahaditya Alrasyidi Hanggoro
Avinindita Nura Lestari
Kristy Iskandar
Andi Dwihantoro
Eko Purnomo
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Pediatrics / Ausgabe 1/2024
Elektronische ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-024-04682-6

Weitere Artikel der Ausgabe 1/2024

BMC Pediatrics 1/2024 Zur Ausgabe

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.